OVID:NASDAQ, Ovid Therapeutics Inc.
OVID stock overview
Ovid Therapeutics Inc. (OVID:NASDAQ) closed at $2.54 on November 13, 2026,
down 0.39% on the day.
The stock trades 18.2% below its 52-week high of $3.11
and 115.3% above its 52-week low of $1.18.
Over the past year, it gained 94.6%.
Ovid Therapeutics Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $2.54
- Day change
- -0.39%
- Volume
- 2,900,217
- Average volume
- 1,906,365
- Market cap
- 479M+
- 52-week range
- $1.18 – $3.11
- 50-day average
- $2.51
- 200-day average
- $2.41
Price action over the past year
In 252 trading sessions since November 13, 2025, OVID closed higher on 119 days (47%).
Its best day was December 22, 2025 (+21.77%) and its worst was January 28, 2026 (-14.36%).
The stock moved 10% or more in a single session 13 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
OVID news
-
Nov 10, 2026:
VC funding in Europe falls short at early-stage investment hurdles
-
Nov 10, 2026:
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
-
Nov 6, 2026:
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
-
Nov 5, 2026:
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates
-
Nov 5, 2026:
Ovid Therapeutics to Participate in Upcoming Investor Conferences
-
Oct 15, 2026:
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
-
Oct 8, 2026:
Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329
-
Sep 12, 2026:
Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a US-based biopharmaceutical company. The firm is engaged primarily in developing medicines for patients suffering with rare neurological disorders.
Similar stocks
Find more stocks like OVID with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.